Displaying drugs 2376 - 2400 of 3589 in total
KAHR-102
KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
Investigational
TSHA-104
Investigational
IBIO-100
IBIO-100 is a high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein.
Investigational
TSHA-101
Investigational
MDX-1097
MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA).
Investigational
TSHA-102
TSHA-102 is a recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene.
Investigational
AOC-1020
AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4.
Investigational
CRA_10433
Experimental
ADX-10061
ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.
Investigational
Matched Iupac: … (5S)-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol …
ONCOS‐102
Investigational
VB10.16
VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers. It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting cells (APCs).
Investigational
BN104
Investigational
KB105
Investigational
Poloxamer 331
Investigational
Redaporfin
Investigational
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Pegozafermin
Pegozafermin is under investigation in clinical trial NCT05852431 (To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia).
Investigational
Anti-SARS-CoV-2 REGN-COV2
Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered...
Investigational
Iron polymaltose
Experimental
Matched Products: … FERLOS 20 MG/ML ORAL ÇÖZELTİ, 10 ADET ... VEGAFERON 100 MG/5 ML ORAL ÇÖZELTİ, 10 ADET ... FERTAMİR 40 MG EFERVESAN GRANÜL İÇEREN SAŞE, 10 SAŞE …
KOS-1584
KOS-1584 is a second-generation epothilone. Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-1584 is a second-generation compound with increased potency, favorable tissue distribution, and ease of formulation.
Investigational
Imidapril
Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.
Investigational
Matched Products: … ทานาทริล 10 มก. ชนิดเม็ด ... TANATRIL TABLETS 10 mg …
H3B-8800
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
CRA_10655
Experimental
Displaying drugs 2376 - 2400 of 3589 in total